For health technology assessment (HTA) agencies, cancer drugs provide a special set of challenges and level of complexity in their reimbursement evaluations. Measuring surrogate endpoints, valuing high-cost combination therapies, and keeping up with innovations like immunotherapies are all nuanced examples that are especially challenging in oncology. This Archived Webinar, Is Your Oncology Drug HTA-Ready?, is now available to watch. (Source: Context Matters, 7/27/16)
You are here: / / Is Your Oncology Drug HTA-Ready?